SpringWorks Therapeutics Statistics
Total Valuation
AMRN has a market cap or net worth of $313.55 million. The enterprise value is $22.95 million.
Important Dates
The last earnings date was Wednesday, July 30, 2025, before market open.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AMRN has 20.68 million shares outstanding. The number of shares has increased by 0.79% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 20.68M |
| Shares Change (YoY) | +0.79% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 3.59% |
| Owned by Institutions (%) | 12.85% |
| Float | 18.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.16 |
| PS Ratio | 1.37 |
| Forward PS | 1.88 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.26 |
| Quick Ratio | 2.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,314.14 |
Financial Efficiency
Return on equity (ROE) is -20.38% and return on invested capital (ROIC) is -6.18%.
| Return on Equity (ROE) | -20.38% |
| Return on Assets (ROA) | -4.35% |
| Return on Invested Capital (ROIC) | -6.18% |
| Return on Capital Employed (ROCE) | -10.57% |
| Revenue Per Employee | $797,676 |
| Profits Per Employee | -$376,684 |
| Employee Count | 275 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 0.49 |
Taxes
In the past 12 months, AMRN has paid $5.07 million in taxes.
| Income Tax | 5.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.14% in the last 52 weeks. The beta is 0.83, so AMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +11.14% |
| 50-Day Moving Average | 14.32 |
| 200-Day Moving Average | 11.39 |
| Relative Strength Index (RSI) | 49.95 |
| Average Volume (20 Days) | 83,178 |
Short Selling Information
| Short Interest | 413,785 |
| Short Previous Month | 448,322 |
| Short % of Shares Out | 2.91% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.37 |
Income Statement
In the last 12 months, AMRN had revenue of $219.36 million and -$103.59 million in losses. Loss per share was -$5.02.
| Revenue | 219.36M |
| Gross Profit | 118.67M |
| Operating Income | -51.20M |
| Pretax Income | -27.02M |
| Net Income | -103.59M |
| EBITDA | -48.25M |
| EBIT | -51.20M |
| Loss Per Share | -$5.02 |
Full Income StatementBalance Sheet
The company has $298.70 million in cash and $9.55 million in debt, giving a net cash position of $289.15 million or $13.98 per share.
| Cash & Cash Equivalents | 298.70M |
| Total Debt | 9.55M |
| Net Cash | 289.15M |
| Net Cash Per Share | $13.98 |
| Equity (Book Value) | 464.92M |
| Book Value Per Share | 22.38 |
| Working Capital | 420.87M |
Full Balance SheetCash Flow
| Operating Cash Flow | -11.52M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.52M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
Gross margin is 54.10%, with operating and profit margins of -23.34% and -47.22%.
| Gross Margin | 54.10% |
| Operating Margin | -23.34% |
| Pretax Margin | -44.91% |
| Profit Margin | -47.22% |
| EBITDA Margin | -22.00% |
| EBIT Margin | -23.34% |
| FCF Margin | n/a |
Dividends & Yields
AMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.79% |
| Shareholder Yield | -0.79% |
| Earnings Yield | -33.19% |
| FCF Yield | -3.69% |
Analyst Forecast
The average price target for AMRN is $12.00, which is -20.84% lower than the current price. The consensus rating is "Strong Sell".
| Price Target | $12.00 |
| Price Target Difference | -20.84% |
| Analyst Consensus | Strong Sell |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 1.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 11, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
AMRN has an Altman Z-Score of -2.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.03 |
| Piotroski F-Score | 2 |
